Prostate-Specific Membrane Antigen (PSMA) is currently used as a target in developing radiopharmaceutical agents for imaging and treatment of prostate cancer because about 90–100% of prostate cancer cases experience PSMA overexpression [209]. This evidence concerns the gene FOLH1 and prostate cancer.